CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Neurobehavioral testing +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00937794
NCT00937794N/ACompleted

A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®

Shire·observational·Posted Jul 13, 2009·Updated Jun 14, 2021

In Brief

An observational study evaluating Neurobehavioral testing and Visual and auditory assessments for Hunter Syndrome. Completed, enrolled 33 participants across 2 sites in 2 countries.

Detailed Summary

This study is being conducted to identify pediatric patients with Hunter syndrome who have neurodevelopmental disease characteristics, who are currently receiving treatment with Elaprase, and who may be suitable to participate in a clinical study with an investigational agent.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHunter Syndrome
CountriesUnited Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2009
Enrollment StartJul 2, 2009
Primary CompletionJul 13, 2011
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 17.0 years ago

Interventions

Neurobehavioral testingbehavioral

If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.

Visual and auditory assessmentsother

If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.